More work needed for EU RMP initiative to be fully beneficial, says generics industry
This article was originally published in SRA
Executive Summary
The EU generics industry says that while a new initiative that aims to help drug makers in the EU, especially generics companies, prepare risk management plans is a step in the "right direction", "further steps" are needed to ensure that the initiative is fully beneficial for the sector1-3.